• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Spartan Capital Securities, LLC Announces Key February Transactions

    3/7/25 4:56:47 PM ET
    $HCTI
    $LIPO
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCTI alert in real time by email

    New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries.

    Spartan Capital successfully served as the sole placement agent for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) in a $3.788 million private placement. This financing represents an important milestone in Lipella's efforts to advance its clinical pipeline and address significant unmet medical needs under the leadership of CEO Dr. Jonathan Kaufman.

    The firm also played a key role as Co-Placement Agent in Healthcare Triangle, Inc.'s (NASDAQ:HCTI) $15.2 million private placement, securing $14.2 million of the total offering. The proceeds will support Healthcare Triangle's strategic acquisitions, general corporate purposes, and working capital needs, enabling the company to further its mission of driving digital transformation in healthcare and life sciences through cloud enablement, cybersecurity, and data analytics.

    "These transactions highlight Spartan Capital's ability to deliver meaningful results for our clients," said John Lowry, CEO of Spartan Capital Securities, LLC. "We take pride in our role as a trusted partner, helping companies secure the capital they need to fuel innovation, execute strategic growth initiatives, and drive long-term success. Our investment banking team remains committed to delivering exceptional service and tailored financial solutions across diverse industries."

    Spartan Capital extends its gratitude to Sichenzia Ross Ference Carmel LLP for their expert legal representation of Spartan Capital in the Lipella Pharmaceuticals transaction and Sullivan & Worcester LLP for representing Lipella Pharmaceuticals. Additionally, we appreciate the contributions of RBW Capital Partners LLC (a division of Dawson James Securities, Inc.), Sichenzia Ross Ference Carmel LLP, and Manatt, Phelps & Phillips, LLP in the Healthcare Triangle placement.

    These February transactions exemplify Spartan Capital Securities' ongoing commitment to providing impactful investment banking solutions. With a deep understanding of market dynamics and a focus on delivering strategic financial solutions, Spartan Capital remains dedicated to supporting clients in achieving their long-term goals.

    As we continue into 2025, Spartan Capital is excited about the opportunities ahead and remains committed to delivering excellence in investment banking.

    About Spartan Capital Securities, LLC

    Spartan Capital Securities, LLC is a full-service, integrated financial services firm providing strategic investment banking solutions to high-net-worth individuals and institutions. With deep market expertise and a steadfast commitment to client success, Spartan Capital continues to set the standard for excellence in the financial industry.

    Contact:

    Spartan Capital Securities, LLC

    45 Broadway, 19th Floor

    New York, NY 10006

    [email protected]



    Primary Logo

    Get the next $HCTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCTI
    $LIPO

    CompanyDatePrice TargetRatingAnalyst
    More analyst ratings

    $HCTI
    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WallachBeth Capital Announces Healthcare Triangle Warrant Inducement For Aggregate Gross Proceeds Of $1.63 Million

    JERSEY CITY, N.J., Oct. 2, 2025 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 812,775 of the Company's shares of common stock (the "Existing Warrants"). In consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds of approximately $1.63 million, the exercising holder

    10/2/25 11:40:00 AM ET
    $HCTI
    EDP Services
    Technology

    Healthcare Triangle Subsidiary QuantumNexis Reports $20M in Consumption-Based Revenue Processed on Ezovion Platform, Forecasts $37M Amid Rapid Growth

    PLEASANTON, Calif., Oct. 1, 2025 /PRNewswire/ -- Healthcare Triangle, Inc. (NASDAQ:HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announced a significant milestone for its wholly-owned subsidiary, QuantumNexis. QuantumNexis's Ezovion Electronic Medical Record (EMR) platform has processed over $20 million in revenue generated by healthcare providers who rely on the platform to digitize and manage their operations. This milestone underscores Ezovion's expanding role as the digital infrastructure powering hospitals, clinics, and specialty care providers across multiple markets, enabling seamless digitization, streamlined wo

    10/1/25 8:00:00 AM ET
    $HCTI
    EDP Services
    Technology

    Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

    All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profileStatistically significant improvements achieved across all efficacy endpoints at the 4-week timepointPreparing to initiate a pivotal Phase 2b study to advance LP-10 toward registration PITTSBURGH, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company transforming care with innovative mucosal delivery solutions, today announced positive final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary liposomal tacrolimus oral rinse, in pa

    9/18/25 8:00:00 AM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCTI
    $LIPO
    SEC Filings

    View All

    SEC Form PRE 14C filed by Healthcare Triangle Inc.

    PRE 14C - Healthcare Triangle, Inc. (0001839285) (Filer)

    10/2/25 5:00:01 PM ET
    $HCTI
    EDP Services
    Technology

    SEC Form PRE 14A filed by Healthcare Triangle Inc.

    PRE 14A - Healthcare Triangle, Inc. (0001839285) (Filer)

    9/30/25 4:20:50 PM ET
    $HCTI
    EDP Services
    Technology

    Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

    9/18/25 8:01:38 AM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCTI
    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Kaufman Jonathan H

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    4/7/25 7:16:11 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Business Head Kannappan Lakshmanan acquired 304,180 shares, increasing direct ownership by 1,521% to 324,180 units (SEC Form 4)

    4 - Healthcare Triangle, Inc. (0001839285) (Issuer)

    4/2/25 5:13:23 PM ET
    $HCTI
    EDP Services
    Technology

    Head of M&A Kizhakevilayil Shibu acquired 34,129 shares, increasing direct ownership by 171% to 54,129 units (SEC Form 4)

    4 - Healthcare Triangle, Inc. (0001839285) (Issuer)

    4/2/25 5:12:34 PM ET
    $HCTI
    EDP Services
    Technology

    $HCTI
    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    5/15/24 4:39:19 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

    4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

    3/19/24 6:21:08 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCTI
    $LIPO
    Leadership Updates

    Live Leadership Updates

    View All

    Healthcare Triangle, Inc. Appoints Anand Kumar as Interim CEO

    PLEASANTON, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc. (NASDAQ:HCTI) ("Healthcare Triangle," "HCTI" or the "Company"), a frontrunner in healthcare technology has announced the appointment of Anand Kumar as the interim Chief Executive Officer alongside his current role as the Chief Revenue Officer. Anand is committed to leading the Company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, Artificial Intelligence (AI) and Large Language Models (LLM). With a wealth of experience and a track record of successfully leading initiatives, Anand is strategically positioned to guide HCTI through its next phase of

    3/12/24 9:41:00 AM ET
    $HCTI
    EDP Services
    Technology

    $HCTI
    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:09:22 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

    SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    11/14/24 5:00:15 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

    SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

    10/17/24 5:00:44 PM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCTI
    $LIPO
    Financials

    Live finance-specific insights

    View All

    Healthcare Triangle, Inc. Releases Shareholder Update

    Highlights Market Opportunity and Recent Accretive Acquisition Awarded Top 100 Premier Partner Status at Amazon World Services & Premier Partner Status at Google Cloud PLEASANTON, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc., (NASDAQ:HCTI) ("HCTI" or the "Company") a leading provider of cloud and data transformation platform and solutions for healthcare and life sciences, today released a shareholder update: Dear Shareholders: Thank you for your continued commitment and investment in Healthcare Triangle, Inc . Our progress over the past year would not have been possible without your trust and belief in our mission. This is our first shareholder update since our

    1/20/22 8:30:00 AM ET
    $HCTI
    EDP Services
    Technology

    Healthcare Triangle (HCTI) Acquires DevCool, an Electronic Health Record (EHR) Focused Healthcare IT and Managed Services Company

    PLEASANTON, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (HCTI), a leading provider of Healthcare and Life Sciences cloud transformation, managed services and data analytics platform company, announced today that it has acquired DevCool, Inc. ("DevCool"), ranked by Inc. 5000 as among the fastest growing private companies in USA in 2021. DevCool provides EHR Implementation and Managed Services to 6 of the top 10 hospitals in the USA and specializes in providing services to cancer research hospitals and university medical centres. The combined entity will focus on accelerating healthcare providers to adopt cloud technologies in improving clinical, operational, and fin

    12/13/21 8:00:00 AM ET
    $HCTI
    EDP Services
    Technology